Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 17, 2017 - Issue 6
Submit an article Journal homepage
650
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe

Fanni RenczDepartment of Health Economics, Corvinus University of Budapest, Budapest, HungaryView further author information
,
László GulácsiDepartment of Health Economics, Corvinus University of Budapest, Budapest, HungaryCorrespondence[email protected]
View further author information
,
Márta PéntekDepartment of Health Economics, Corvinus University of Budapest, Budapest, HungaryView further author information
,
Krisztina B. Gecse1st Department of Medicine, Semmelweis University, Budapest, HungaryView further author information
,
Axel DignassDepartment of Medicine 1, Agaplesion Markus Krankenhaus, Frankfurt, GermanyORCID Iconhttp://orcid.org/0000-0002-9724-054XView further author information
ORCID Icon,
Jonas HalfvarsonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, SwedenView further author information
,
Fernando GomollónGastroenterology Unit, Clinical Universitary Hospital Lozano IIS Aragón (Blesa, IIS Aragón, CIBEREHD), Zaragoza, SpainView further author information
,
Petra BajiDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungary;Center for Economic Research and Graduate Education (CERGE) Economics Institute (EI) Research Fellow, Charles University, Praha 1, The Czech RepublicView further author information
,
Laurent Peyrin-BirouletInserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, Lorraine University, Vandoeuvre-lès-Nancy, FranceView further author information
,
Peter L. Lakatos1st Department of Medicine, Semmelweis University, Budapest, HungaryView further author information
&
Valentin BrodszkyDepartment of Health Economics, Corvinus University of Budapest, Budapest, HungaryView further author information
 show all
Pages 597-606 | Received 14 Jan 2017, Accepted 20 Apr 2017, Published online: 28 Apr 2017

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Pochamana Phisalprapa, Chayanis Kositamongkol, Julajak Limsrivilai, Satimai Aniwan, Phunchai Charatcharoenwitthaya, Pises Pisespongsa, Taya Kitiyakara, Suporn Treepongkaruna & Nathorn Chaiyakunapruk. (2020) Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand. Journal of Medical Economics 23:11, pages 1302-1310.
Read now
Zsuzsanna Kurti, Lorant Gonczi & Peter L. Lakatos. (2018) Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opinion on Biological Therapy 18:6, pages 633-640.
Read now

Articles from other publishers (20)

Yoram Bouhnik, Raja Atreya, Daniel Casey, Michał Górecki, Deborah Baik, Sang Wook Yoon, Taek Sang Kwon & Minyoung Jang. (2023) Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflammatory Bowel Diseases 29:6, pages 898-913.
Crossref
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N Bernstein, Gilaad G Kaplan, Dana Duricova, Dan Greenberg, Hans O Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valérie E H Pittet, Vito Annese, KT Park, Konstantinos H Katsanos, Marte L Høivik, Zeljko Krznaric, María Chaparro, Edward V LoftusJrJr, Peter L Lakatos, Javier P Gisbert, Willem Bemelman, Bjorn Moum, Richard B Gearry, Michael D Kappelman, Ailsa Hart, Marieke J Pierik, Jane M Andrews, Siew C Ng, Renata D'Inca & Pia Munkholm. (2023) The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology 8:5, pages 458-492.
Crossref
Naazish S. Bashir, Avery Hughes & Wendy J. Ungar. (2023) Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. MDM Policy & Practice 8:1.
Crossref
Zhanhui Zhu, Yang Lei & Zheng Lin. (2023) Effects of Crohn’s disease exclusion diet on remission: a systematic review. Therapeutic Advances in Gastroenterology 16.
Crossref
Silvia Marquez-Megias, Ricardo Nalda-Molina, Javier Sanz-Valero, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix & Amelia Ramon-Lopez. (2022) Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics 14:5, pages 1009.
Crossref
Jiri Bronsky, Ivana CopovaDenis KazekaTereza LerchovaKatarina MitrovaKristyna PospisilovaMiroslava SulovcovaKristyna ZarubovaOndrej Hradsky. (2022) Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation. Clinical and Translational Gastroenterology 13:5, pages e00490.
Crossref
Henit Yanai, Arie Levine, Ayal Hirsch, Rotem Sigall Boneh, Uri Kopylov, Hagar Banai Eran, Nathaniel A Cohen, Yulia Ron, Idan Goren, Haim Leibovitzh, Joram Wardi, Eran Zittan, Tomer Ziv-Baran, Lee Abramas, Naomi Fliss-Isakov, Barbara Raykhel, Tamar Pfeffer Gik, Iris Dotan & Nitsan Maharshak. (2022) The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. The Lancet Gastroenterology & Hepatology 7:1, pages 49-59.
Crossref
Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone & Edoardo Vincenzo Savarino. (2021) Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. Therapeutic Advances in Gastroenterology 14, pages 175628482110233.
Crossref
Bruna de Oliveira Ascef, Ana Carolina de Freitas Lopes & Patrícia Coelho de Soárez. (2020) Health technology assessment of biosimilars worldwide: a scoping review. Health Research Policy and Systems 18:1.
Crossref
Frank I Scott, Michelle Luo, Yash Shah, Karen Lasch, Ravy K Vajravelu, Ronac Mamtani, Blair Fennimore, Mark E Gerich & James D Lewis. (2020) Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. Journal of Crohn's and Colitis 14:5, pages 575-587.
Crossref
Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar & Edward V. Loftus. (2020) Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intestinal Research 18:1, pages 34-44.
Crossref
Abhinav Vasudevan, Peter R Gibson & Daniel R Van Langenberg. (2019) Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:9, pages 1462-1473.
Crossref
Fanni Rencz, Peep F. M. Stalmeier, Márta Péntek, Valentin Brodszky, Gábor Ruzsa, Lóránt Gönczi, Károly Palatka, László Herszényi, Eszter Schäfer, János Banai, Mariann Rutka, László Gulácsi & Peter L. Lakatos. (2019) Patient and general population values for luminal and perianal fistulising Crohn’s disease health states. The European Journal of Health Economics 20:S1, pages 91-100.
Crossref
Lorant Gonczi, Akos Ilias, Zsuzsanna Kurti & Peter L. Lakatos. (2019) Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?. Current Pharmaceutical Design 25:1, pages 13-18.
Crossref
Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet & Peter L. Lakatos. (2019) Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry 26:2, pages 259-269.
Crossref
Fanni Rencz, Peter L. Lakatos, László Gulácsi, Valentin Brodszky, Zsuzsanna Kürti, Szilvia Lovas, János Banai, László Herszényi, Tamás Cserni, Tamás Molnár, Márta Péntek & Károly Palatka. (2018) Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease. Quality of Life Research 28:1, pages 141-152.
Crossref
Ágnes Milassin, Anna Fábián & Tamás Molnár. (2019) Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therapeutic Advances in Gastroenterology 12, pages 175628481984274.
Crossref
Alain Attar, Gérard Duru, Xavier Roblin, Bernard Savarieau, Pierre Brunel, Michel Lamure & Laurent Peyrin-Biroulet. (2019) Cost savings using a test-based de-escalation strategy for patients with Crohn’s disease in remission on optimized infliximab: A discrete event model study. Digestive and Liver Disease 51:1, pages 112-119.
Crossref
Joanna Sieczkowska-Golub, Dorota Jarzebicka, Grzegorz Oracz & Jaroslaw Kierkus. (2018) Biosimilars in paediatric inflammatory bowel disease. World Journal of Gastroenterology 24:35, pages 4021-4027.
Crossref
Przemysław Holko, Paweł Kawalec & Andrzej Pilc. (2018) Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. PharmacoEconomics 36:7, pages 853-865.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.